Gerostate Alpha

Gerostate Alpha is a biotech company focused on developing therapeutics for aging. Aging is the single largest biomedical problem in the world, with annual costs in the trillions. We believe the time is right to develop therapeutics targeting aging. Our goal is to reduce the impact of aging now.

Aging is often called the "Climate change of biology". It is a problem that has challenged humanity for millennia. Recent breakthroughs in biomedical science now enable rapid progress in slowing aging in animal models. We aim to translate such studies into drugs for the global population.

We can already screen potential drugs in simple animal models to extend their lifespan. The challenge for us is to translate that into robust pharmaceuticals. Such drugs would dramatically improve the quality of life for the global population, as at some stage everyone begins to suffer from the maladies of age. We are on the precipice of a bold new era in drugs that modulate the aging process itself.

We have developed a technology platform which enables rapid identification of novel molecules which target fundamental aspects of aging. Our platform takes these hits, and moves them into screens in mice where we evaluate robust metrics of aging with translatable parallels in the aging human population. We have built this platform based on decades of experience at the forefront of academic research in the biology of aging.

Pre -series A, 2nd seed.

The global aging population. TAM - everyone who ages This is not hyperbole.

Juvenescence Unity Calico Bioage Life Biosciences Incubating at the Buck Institute (top research institute for aging in the world), leveraging our experience in manipulating aging in lab animals over the last few decades.

Discover pharmaceuticals which slow aging, license to Pharma, potential direct sales of natural products which slow aging in the lab.

Simon Melov PhD CEO Mark Lucanic Phd CSO Gordon Lithgow PhD Vice President of the Buck Institute Edward Lanphier (founding CEO of Sangamo therapeutics, (Nasdaq: SGMO)) Executive Chair

Previously raised $2.1M, with a 1M investment from Ycombinator, and $500,000 from CRCM (balance from angel entrepreneurs)

Raising $3M via SAFE

We are developing a series of lead molecules targeting aging.